Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.38 |
| ▸ | F2 | P00734 | 10/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001019 | 0.90 | CXCR3 (0.36) | F10F2CTRB1HTR2CMCHR1 | |
| SCHEMBL2006337 | 0.86 | SMO (0.40) | NR3C1PGR | |
| SCHEMBL2001547 | 0.86 | SMO (0.40) | NR3C1PGR | |
| SCHEMBL1998341 | 0.85 | HTR7 (0.38) | F10F2HTR2CMCHR1PDCD1 | |
| SCHEMBL2003024 | 0.85 | HTR2C (0.37) | F10F2CTRB1HTR2CMCHR1 | |
| SCHEMBL5228002 | 0.84 | TSHR (0.39) | HTR2CMCHR1 | |
| SCHEMBL5228047 | 0.83 | HTR2C (0.37) | F10HTR2CMCHR1 | |
| SCHEMBL1998836 | 0.82 | HTR2C (0.39) | F10F2HTR2CMCHR1 | |
| SCHEMBL2760900 | 0.81 | MCHR1 (0.39) | HTR2CMCHR1 | |
| SCHEMBL5225875 | 0.81 | CYP2D6 (0.36) | PDCD1CD274NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960413-B2 | Pyrazole compounds | MERCK PATENT GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| EP-1611094-B1 | PYRAZOLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2007-06-20 | — | — | EP | disclosed |
| US-20060276650-A1 | Pyrazole compounds | MERCK PATENT GMBH (DE) | 2006-12-07 | — | — | US | disclosed |
| EP-1611094-A1 | PYRAZOLE COMPOUNDS | MERCK PATENT GmbH (DE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089888-A1 | PYRAZOLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276650-A1 | Pyrazole compounds | HTR1D, HTR1A, HTR3A | F10 1408/4885F2 933/4885CTRB1 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.